HealthDay - FDA Probing Possible Link Between Asthma Drug and Suicide Risk
The U.S. Food and Drug Administration said Thursday it was investigating the possibility of an increased risk of mood changes and suicidal behavior among those who take the highly popular asthma drug Singulair.
Singulair is the number one-selling drug among people aged 17 and younger. Last year, it posted sales of $4.3 billion, making it Merck & Co.’s top-selling product, according to the Associated Press .
In issuing its statement, the FDA stressed that asthma patients should not stop taking Singulair without talking to their doctor first.
Related Results
SingulairSingulair labelSingulair Sales.Singulair, veramyst nasal sprayNew Singulair aerator
Both Merck and the FDA noted that the two have been working together over the past year to determine the scope of the problem and to make appropriate labeling changes to reflect the potential risk of mood changes and suicidal behavior among Singulair users.
“Suicide has been reported to us only in post-marketing experience in anecdotal reports that come …
Read the full article with a Free Trial at MyWire.
